Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP:249908AA2) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP:04545LAA5) (together, the “Notes”). The Offers are being made on the terms and subject to the conditions set forth in an Offer to Purchase dated March 11, 2020 (the “Offer to Purchase”) and are scheduled to expire at 11:59 p.m., New York City time, on April 7, 2020 unless extended by the Company (the “Expiration Time”). Holders of the Notes who have tendered (and not validly withdrawn) their Notes at or prior to the Expiration Time will be entitled to receive in cash $995 per $1,000 principal amount of Notes validly tendered (and not validly withdrawn), plus accrued and unpaid interest on such Notes up to, but not including, the date the Offers are settled which is expected to be promptly following the expiration of the Offers.
If you're interested in Assertio Therapeutics, Inc. (NASDAQ:ASRT), then you might want to consider its beta (a measure...
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible.
URGENT: STOCKHOLDER VOTE MAY 19, 2020
Zyla Life Sciences (OTCQX: ZCOR), a Wayne-based specialty pharmaceutical company that focuses on non-opioid pain products, has entered into a definitive merger agreement with Assertio Therapeutics. Zyla will operate as a subsidiary of the new holding company.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Assertio Therapeutics, Inc. ("Assertio Therapeutics" or the "Company") (NasdaqGS: ASRT) relating to the creation of a combined company between the Company and Zyla Life Sciences. Under the terms of the agreement, Assertio Therapeutics will issue 2.5 shares to each Zyla stockholder. Assertio Therapeutics stockholders will own 68% and Zyla stockholders will own 32% of the combined company.
Assertio Therapeutics, Inc. (NASDAQ:ASRT) shareholders will have a reason to smile today, with the covering analyst...
Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., ("Assertio" ) (NASDAQ: ASRT) announced the closing of the merger with Zyla Life Sciences. The combined company (the "Company") will operate under the Assertio name and trade on Nasdaq under the ticker ASRT.
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / May 8, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Assertio Therapeutics, Inc. (NASDAQ:ASRT) and Zyla Life Sciences ...
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
NEW YORK, March 17, 2020 -- Halper Sadeh LLP, a global investor rights law firm, investigates whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP.
Assertio Therapeutics, Inc. (“Assertio” or “the Company”) (ASRT) today announced the date of its 2020 Annual Meeting, which will be held as a virtual meeting on May 19, 2020. The Company also announced the mailing of a joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”) to stockholders. At the 2020 Annual Meeting, the Company will ask its stockholders, among other things, to approve the issuance of shares to stockholders of Zyla Life Sciences (“Zyla”) in connection with the Company’s previously announced merger with Zyla (the “Merger”).
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Assertio Therapeutics, Inc. (NASDAQ: ASRT) and Zyla Life Sciences is fair to Assertio shareholders.
Assertio Therapeutics, Inc. (“Assertio” or “the Company”) (ASRT) and Zyla Life Sciences (“Zyla”) (ZCOR), today announced that they have entered into a definitive merger agreement (the “Agreement”). Under the terms of the Agreement, upon the effective time of the merger (the “Merger”), Zyla stockholders will be entitled to receive 2.5 shares of common stock of a newly-formed holding company for each share of Zyla common stock held and the newly combined company will retain the Assertio name and trade on Nasdaq under the ASRT ticker.
Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 11, 2020View more earnings on ASRTTime: 08:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/vryis85cTechnicals 52-week high: $4.92Company's 52-week low was at $0.55Price action over last quarter: Up 10.80%Company Description Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.See more from Benzinga * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 20 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Maple Leaf Foods Inc. (the "Company") today announced that it has filed its 2020 notice of annual meeting of shareholders and management information circular and copies are now available online at www.mapleleaffoods.com and on SEDAR at www.sedar.com.
Maple Leaf Foods Inc. (the "Company") today announced that the Toronto Stock Exchange (the "TSX") has accepted the notice filed by the Company to establish a normal course issuer bid ("NCIB") program.
Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP:249908AA2) (“2021 Notes”) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP:04545LAA5) (“2024 Notes”, together with the 2021 Notes, the “Notes”). The Offers were made on the terms and subject to the conditions set forth in an Offer to Purchase dated March 11, 2020 (the “Offer to Purchase”) and expired at 11:59 p.m., New York City time, on April 7, 2020 (the “Expiration Time”). As of the Expiration Time of the Offers, $42,130,000 aggregate principal of 2021 Notes and $34,522,000 aggregate principal of 2024 Notes have been validly tendered and not validly withdrawn (the “Accepted Notes”).